ECOG E1105: A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab; Carboplatin; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- 06 Feb 2017 Biomarkers information updated
- 10 Apr 2013 Planned end date changed from 1 Mar 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 07 Jan 2013 Planned end date changed from 1 May 2011 to 1 Mar 2013 as reported by ClinicalTrials.gov.